<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">Iron-overload</z:e> induced <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is a major cause of morbidity and mortality in thalassemic patients </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies suggest that cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction may be involved in the pathogenesis of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the hypothesis that <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> causes dysfunction of cardiac mitochondria isolated from thalassemic mice </plain></SENT>
<SENT sid="3" pm="."><plain>Cardiac mitochondria were isolated from the heart tissue of genetically-altered, β-thalassemic mice (HT) and adult <z:mp ids='MP_0002169'>wild-type</z:mp> mice (WT) </plain></SENT>
<SENT sid="4" pm="."><plain>Ferrous iron (Fe(2+)) at various concentrations (0-5 μg/ml) was applied to induce iron toxicity </plain></SENT>
<SENT sid="5" pm="."><plain>Pharmacological interventions, facilitated by <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> permeability transition pore (mPTP) blocker, CsA, and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> Ca(2+) uniporter (MCU) blocker, Ru360, were used to study their respective effects on cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction </plain></SENT>
<SENT sid="6" pm="."><plain>Cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ROS production, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential changes, and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> swelling were determined </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">Iron overload</z:e> caused increased ROS production, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> depolarization, and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> swelling in a dose-dependent manner in WT and HT cardiac mitochondria </plain></SENT>
<SENT sid="8" pm="."><plain>CsA decreased only ROS production in WT and HT cardiac mitochondria, whereas Ru360 completely prevented the development of cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction by decreasing ROS, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> depolarization, and swelling in both WT and HT cardiac mitochondria </plain></SENT>
<SENT sid="9" pm="."><plain>Ru360, an MCU blocker, provides protective effects by preventing ROS production and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> depolarization as well as attenuating <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> swelling caused by Fe(2+) overload </plain></SENT>
<SENT sid="10" pm="."><plain>These findings indicate that the MCU could be a major portal for Fe(2+) entry into cardiac mitochondria </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, blocking MCU may be an effective therapy to prevent <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron-overload</z:e> induced cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction in patients with <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> </plain></SENT>
</text></document>